TG Therapeutics Inc vs T-Mobile Us Inc — how do they compare? TG Therapeutics Inc trades at $54.06 (market cap $8.26B), while T-Mobile Us Inc trades at $190.5 (market cap $211.72B). The key difference: T-Mobile Us Inc is far larger — about 25.6× TG Therapeutics Inc's market cap, and T-Mobile Us Inc pays a 2.09% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | TMUS | |
|---|---|---|
Market Cap | $8.26B | $211.72B |
Sector | Health | Media |
52-Week High | $59.06 | $259.01 |
52-Week Low | $26.39 | $167.65 |
Enterprise Value | $8.50B | $329.42B |
Dividend Yield | — | 2.09% |
Trailing returns across standard periods
Latest headlines on both assets
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →